Cargando…
Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients
BACKGROUND: High-dose Interferon (HDI) therapy produces a clinical response and achieves relapse-free survival in 20-33% of patients with operable high risk or metastatic melanoma. However, patients may develop significant side effects frequently necessitating dose reduction or discontinuation of th...
Autores principales: | Simons, Diana L, Lee, Gerald, Kirkwood, John M, Lee, Peter P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114759/ https://www.ncbi.nlm.nih.gov/pubmed/21545749 http://dx.doi.org/10.1186/1479-5876-9-52 |
Ejemplares similares
-
Adjuvant interferon in the treatment of melanoma
por: Kirkwood, J M
Publicado: (2000) -
Induction of γ‐Interferon by Avarol in Human Peripheral Blood Lymphocytes
por: Voth, Rita, et al.
Publicado: (1988) -
Down-Regulation of the Interferon Signaling Pathway in T Lymphocytes from Patients with Metastatic Melanoma
por: Critchley-Thorne, Rebecca J, et al.
Publicado: (2007) -
Adjuvant therapy of melanoma with interferon: lessons of the past decade
por: Ascierto, Paolo A, et al.
Publicado: (2008) -
Autologous Enhancement by Interferon of Natural Killer Activity of
Human Peripheral Blood Lymphocytes
por: Cheknev, S. B., et al.
Publicado: (1994)